Doruk Erkan

Doruk Erkan

Auto-generated profile, based on publicly available information

Doruk Erkan

Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2023 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
MBMedha Barbhaiya
Medha Barbhaiya
SZStephane Zuily
Stephane Zuily
RNRay Naden
Ray Naden
AHAlison Hendry
Alison Hendry
FMFlorian Manneville
Florian Manneville
TCThe Acr/Eular Aps Classification Criteria Collaborators
The Acr/Eular Aps Classification Criteria Collaborators

28 August 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
MBMedha Barbhaiya
Medha Barbhaiya
SZStephane Zuily
Stephane Zuily
RNRay Naden
Ray Naden
AHAlison Hendry
Alison Hendry
FMFlorian Manneville
Florian Manneville
RZRay Zuo
Ray Zuo
Objective To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. Methods This international multidisciplinary initiative included four phases: (1) Phase I, criteria generation by surveys and literature review; (2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; (3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and (4) Phase IV, validation using independent adjudicators’ consensus as the gold standard. Results The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL-associated clinical criterion, followed by additive weighted criteria (score range 1–7 points each) clustered into six clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and two laboratory domains (lupus anticoagulant functional coagulation assays, and solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti–β2-glycoprotein I antibodies). Patients accumulating at least three points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria vs the 2006 revised Sapporo classification criteria had a specificity of 99% vs 86%, and a sensitivity of 84% vs 99%. Conclusion These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk-stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research.

28 June 2007 in Arthritis & Rheumatism
Verified
Journal Article
Closed access
PDF file
DEDoruk Erkan
Doruk Erkan
MHMelanie J. Harrison
Melanie J. Harrison
RLRoger Levy
Roger Levy
MPMargaret Peterson
Margaret Peterson
MPMichelle Petri
Michelle Petri
MLMichael D. Lockshin
Michael D. Lockshin

1 November 2013 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
LALaura Andreoli
Laura Andreoli
CCCecilia Chighizola
Cecilia Chighizola
ABAlessandra Banzato
Alessandra Banzato
GPGuillermo J Pons-Estel
Guillermo J Pons-Estel
GJGuilherme Ramire De Jesus
Guilherme Ramire De Jesus
DEDoruk Erkan
Doruk Erkan

1 June 2014 in Autoimmunity Reviews
Verified
Journal Article
Closed access
DEDoruk Erkan
Doruk Erkan
CACassyanne L. Aguiar
Cassyanne L. Aguiar
DADanieli Andrade
Danieli Andrade
HCHannah Cohen
Hannah Cohen
MCMaria J. Cuadrado
Maria J. Cuadrado
MLMichael D. Lockshin
Michael D. Lockshin

2 November 2012 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
DEDoruk Erkan
Doruk Erkan
JVJoAnn Vega
JoAnn Vega
GRGlendalee Ramón
Glendalee Ramón
EKElizabeth Kozora
Elizabeth Kozora
MLMichael D. Lockshin
Michael D. Lockshin
Objective: The primary objective of this study was to evaluate the safety of rituximab in antiphospholipid antibody (aPL)–positive patients with non‐criteria manifestations of antiphospholipid syndrome (APS). The secondary objectives were to evaluate the effect of rituximab on the aPL profile and to evaluate the efficacy of rituximab treatment for non‐criteria manifestations of APS.Methods: In this 12‐month, phase II pilot study, adult aPL‐positive patients with thrombocytopenia, cardiac valve disease, skin ulcer, aPL nephropathy, and/or cognitive dysfunction received 2 doses of rituximab (1,000 mg) on days 1 and 15. Antiphospholipid antibody profiles and clinical outcome measures, which were categorized as complete response, partial response, no response, or recurrence, were analyzed at preset time points.Results: Two of 19 patients experienced infusion reactions, resulting in early termination. Twelve serious adverse events and 49 nonserious adverse events were recorded. All patients who had positive results of lupus anticoagulant, anticardiolipin, and anti–β2‐glycoprotein I antibody tests at baseline had positive results at 24 weeks and 52 weeks. The numbers of patients with a complete response, a partial response, no response, and recurrence for the clinical outcome measures at 24 weeks were as follows: for thrombocytopenia, 1, 1, 2, and 0, respectively; for cardiac valve disease, 0, 0, 3, and not analyzed, respectively; for skin ulcer, 3, 1, 0, and 1, respectively; for aPL nephropathy, 0, 1, 0, and 0, respectively; and for cognitive dysfunction, 3, 1, 1, and not analyzed, respectively.Conclusion: The results of this uncontrolled and nonrandomized pilot study suggest that the safety of rituximab in aPL‐positive patients is consistent with the safety profile of rituximab. Despite causing no substantial change in aPL profiles, rituximab may be effective in controlling some but not all non‐criteria manifestations of APS.